EUVIMEDEUVIMED entdecken
Multizentrische Studie

Multicenter Study of Infliximab for Refractory Uveoretinitis in Behçet Disease

Annabelle A Okada, Hiroshi Goto, Shigeaki Ohno, Manabu Mochizuki, Ocular Behçet's Disease Research Group Of Japan

Archives of Ophthalmology · 01.05.2012 · 130 (5) · 592

DOI: 10.1001/archophthalmol.2011.2698 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Archives of Ophthalmology, erschienen am 01.05.2012. Verfasst von Annabelle A Okada und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan. aokada@eye-center.org. Die Arbeit wurde bisher 131-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To describe the effects of infliximab on refractory uveoretinitis in patients with Behçet disease during the first year of treatment. METHODS: Data were collected prospectively at 8 tertiary uveitis centers. Safety was analyzed in 63 patients. Efficacy was analyzed in 50 patients, after exclusion of those who had received infliximab for various reasons before the study. RESULTS: Eighty-nine percent (56 of 63) of the patients were male, with 70% (44 of 63) of the patients aged 25 to 44 years. The safety analysis demonstrated that 34 episodes of adverse effects occurred in 46% (29 of 63) of patients during 1 year, including 3 episodes of infusion reactions. No adverse effects were deemed serious. The efficacy analysis at 1 year showed that uveoretinitis had improved in 69% (33 of 48), had improved somewhat in 23% (11 of 48), was unchanged in 8% (4 of 48), and had worsened in no patients. The mean number of ocular attacks per 6-month period decreased from 2.66 at baseline to 0.44 during months 1 through 6 of infliximab therapy and to 0.79 during months 7 through 12. Forty-four percent (21 of 48) of patients had no ocular attacks during the 1-year period. Efficacy was best for patients with uveoretinitis duration of less than 5 years. The mean best-corrected visual acuity improved logarithm of the minimum angle of resolution from 0.736 at the first infliximab infusion to 0.616 at the end of 1 year (P = .01). CONCLUSIONS: Infliximab treatment for Behçet disease uveoretinitis was well tolerated, with nonserious adverse effects occurring in about half of the patients. At the end of 1 year, uveoretinitis had improved or improved somewhat in 92% (44 of 48) of patients, accompanied by improvement in the mean visual acuity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdolescentAdultAgedAnti-Inflammatory AgentsAntibodies, MonoclonalBehcet SyndromeFemaleHumansInfliximabInfusions, IntravenousMaleMiddle AgedProspective StudiesRecurrenceRetinitisTreatment OutcomeUveitisVisual AcuityYoung Adult

Substanzen

Anti-Inflammatory AgentsAntibodies, MonoclonalInfliximab

Autor:innen und Institutionen

  • Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan. aokada@eye-center.org

Zitieren

APA

Okada, A. A., Goto, H., Ohno, S., Mochizuki, M., & Ocular Behçet's Disease Research Group Of Japan (2012). Multicenter Study of Infliximab for Refractory Uveoretinitis in Behçet Disease. Archives of Ophthalmology, 130(5), 592. https://doi.org/10.1001/archophthalmol.2011.2698

Vancouver

Okada AA, Goto H, Ohno S, Mochizuki M, Ocular Behçet's Disease Research Group Of Japan. Multicenter Study of Infliximab for Refractory Uveoretinitis in Behçet Disease. Archives of Ophthalmology. 2012;130(5):592. doi:10.1001/archophthalmol.2011.2698

BibTeX
@article{Okada2012,
  author = {Okada, Annabelle A and Goto, Hiroshi and Ohno, Shigeaki and Mochizuki, Manabu and Ocular Behçet's Disease Research Group Of Japan, Ocular Behçet's Disease Research Group Of Japan},
  title = {Multicenter Study of Infliximab for Refractory Uveoretinitis in Behçet Disease},
  journal = {Archives of Ophthalmology},
  year = {2012},
  volume = {130},
  number = {5},
  pages = {592},
  doi = {10.1001/archophthalmol.2011.2698}
}
Kostenlos starten →